stem cells

ApprovedSmall molecule

KKang Stem Biotech Co., Ltd.

stem cells is one of 280 small molecule programs targeting Erectile Dysfunction. It is currently in Approved.

Indications

Total Trials

Active Trials

279

Competitors

Pipeline

Status by Indication[3][1]

Indication

Erectile DysfunctionActive, not recruiting

LymphomaActive, not recruiting

Androgenetic AlopeciaActive, not recruiting

AzoospermiaActive, not recruiting

Joint DiseaseActive, not recruiting

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

Motor Neuron DiseaseActive, not recruiting

Myocardial InfarctionActive, not recruiting

XerostomiaActive, not recruiting

Heart FailureActive, not recruiting

Erectile DysfunctionPhase 2/Phase 3

Active, not recruiting

LymphomaPreclinical

Active, not recruiting

Androgenetic AlopeciaPhase 2

Active, not recruiting

AzoospermiaPhase 1/Phase 2

Active, not recruiting

Joint DiseasePhase 1/Phase 2

Active, not recruiting

Chronic Obstructive Pulmonary DiseasePhase 1

Active, not recruiting

Motor Neuron DiseasePhase 1/Phase 2

Active, not recruiting

Myocardial InfarctionPhase 3

Active, not recruiting

XerostomiaPhase 2

Active, not recruiting

Heart FailureApproved

Active, not recruiting

Showing 10 of 12 indications

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

stem cells

KKang Stem Biotech Co., Ltd.

Approved

2 2

Velban

EEastern Cooperative Oncology Group

Preclinical

15 3

Oncaspar

SServier

Preclinical

15 4

Norvir

AbbVie

Preclinical

1 5

Tafasitamab

Incyte

Preclinical

7 6

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 7

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—10

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Chronic Obstructive Pulmonary Disease

NCT06986070

Clinical

Trials by Indication[1]

Myocardial Infarction2 trials

A Study of Allogeneic Low Oxygen Mesenchymal Bone Marrow Cells in Subjects With Myocardial Infarction

Completed·AAltaco XXI, LLP·Phase 3·NCT02672267·50 enrolled

A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With ST Segment Elevation Myocardial Infarction (STEMI)

Withdrawn·SStemedica Cell Technologies, Inc.·Phase 2·NCT01770613

Safety and Efficacy2 trials

Safety and Efficacy of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease(CD)

Unknown status·KKang Stem Biotech Co., Ltd.·Phase 1/2·NCT02000362·24 enrolled

Long-term Safety and Efficacy of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease(CD)

Unknown status·KKang Stem Biotech Co., Ltd.··NCT02926300·24 enrolled

Lymphoma2 trials

A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT01625351·23 enrolled

Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease

Completed·—·N/A·NCT01702961·75 enrolled

Androgenetic Alopecia1 trial

Adipose Tissue Derived Stem Cell Based Hair Restoration Therapy for Androgenetic Alopecia

Completed·KKing Edward Medical University·Phase 2·NCT02865421·22 enrolled

Duchenne Muscular Dystrophy1 trial

Bone Marrow-Derived Autologous Stem Cells for the Treatment of Duchenne Muscular Dystrophy

Unknown status·SStem Cells Arabia·Phase 1/2·NCT03067831·20 enrolled

14 more indications

Allogeneic Stem Cell Transplantation1 trial

T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies

Completed·UUniversity of Chicago·Phase 2·NCT00683046·204 enrolled

Chronic Obstructive Pulmonary Disease1 trial

Investigation of Small Mobile Stem Cells (SMS Cells) in Participants With Chronic Obstructive Pulmonary Disease (COPD).

Recruiting·SSMSbiotech·Phase 1·NCT06986070·18 enrolled

Azoospermia1 trial

Testicular Injection of Autologous Stem Cells for Treatment of Patients With Azoospermia

Unknown status·HHesham Saeed Elshaer·Phase 1/2·NCT02041910·60 enrolled

Xerostomia1 trial

Safety and Efficacy of Mesenchymal Stem Cell for Radiation-induced Hyposalivation and Xerostomia in Previous Head and Neck Cancer Patients

Unknown status·RRigshospitalet, Denmark·Phase 2·NCT04776538·120 enrolled

Premature Ovarian Failure1 trial

Autologous Bone Marrow-Derived Stem Cell Transplantation in Patients With Premature Ovarian Failure (POF)

Unknown status·SStem Cells Arabia·Phase 1/2·NCT03069209·50 enrolled

Motor Neuron Disease1 trial

Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease

Unknown status·SStem Cells Arabia·Phase 1/2·NCT03067857·40 enrolled

Osteoarthritis1 trial

Knee Osteoarthritis Treatment With Adipose-derived Stem Cells: Phase II Clinical Trial

Completed·KKing Faisal Specialist Hospital & Research Center·Phase 2·NCT03308006·18 enrolled

Prevention1 trial

Limbus-derived Stem Cells for Prevention of Postoperative Corneal Haze

Unknown status·LL.V. Prasad Eye Institute·Phase 1·NCT03295292·15 enrolled

Treatment1 trial

MSCs For Treatment of Azoospermic Patients

Completed·—·Phase 1/2·NCT02025270·100 enrolled

Joint Disease1 trial

Stem Cells and Stromal Vascular Fraction for Temporomandibular Joint Disease

Unknown status·TTC Erciyes University·Phase 1/2·NCT05305833·20 enrolled

Stem Cells1 trial

Treatment of Optic Neuropathies Using Autologous Bone Marrow-Derived Stem Cells

Unknown status·SStem Cells Arabia·Phase 1/2·NCT02638714·100 enrolled

Erectile Dysfunction1 trial

The Outcomes of Intracavernosal Umbilical Cord Mesenchymal Stem Cells Implantation in Patients With Diabetic Erectile Dysfunction

Unknown status·IIndonesia University·Phase 2/3·NCT04972890·12 enrolled

Hematologic Malignancies1 trial

T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant

Terminated·SSt. Jude Children's Research Hospital·Phase 2·NCT01621477·34 enrolled

Heart Failure1 trial

Stem Cells Therapy in Advanced Heart Failure

Unknown status·UUniversity of Campania Luigi Vanvitelli·Phase 4·NCT02871466·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 22 trial records for stem cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — stem cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for stem cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kang Stem Biotech Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: KKang Stem Biotech Co., Ltd.

stem cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Myocardial Infarction2 trials

Safety and Efficacy2 trials

Lymphoma2 trials

Androgenetic Alopecia1 trial

Duchenne Muscular Dystrophy1 trial

Allogeneic Stem Cell Transplantation1 trial

Chronic Obstructive Pulmonary Disease1 trial

Azoospermia1 trial

Xerostomia1 trial

Premature Ovarian Failure1 trial

Motor Neuron Disease1 trial

Osteoarthritis1 trial

Prevention1 trial

Treatment1 trial

Joint Disease1 trial

Stem Cells1 trial

Erectile Dysfunction1 trial

Hematologic Malignancies1 trial

Heart Failure1 trial

References

Drug Info

Quick Facts

Related News